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A new common functional coding 
variant at the DDC gene change 
renal enzyme activity and modify 
renal dopamine function
Jose pablo Miramontes-Gonzalez1,3,5, Makena Hightower1, Kuixing Zhang1,3, 
Hiroki Kurosaki2, Andrew J. schork1, Nilima Biswas1,3, Sucheta Vaingankar1,3, 
Manjula Mahata1,3, Michael S. Lipkowitz4, Caroline M. Nievergelt  1, Dewleen G. Baker1,3, 
Michael G. Ziegler1, David León-Jiménez2, Rogelio González-sarmiento1,5, Hiroshi Ichinose2 & 
Daniel T. o’Connor1,3
The intra-renal dopamine (DA) system is highly expressed in the proximal tubule and contributes to 
Na+ and blood pressure homeostasis, as well as to the development of nephropathy. In the kidney, 
the enzyme DOPA Decarboxylase (DDC) originating from the circulation. We used a twin/family study 
design, followed by polymorphism association analysis at DDC locus to elucidate heritable influences 
on renal DA production. Dense single nucleotide polymorphism (SNP) genotyping across the DDC locus 
on chromosome 7p12 was analyzed by re-sequencing guided by trait-associated genetic markers to 
discover the responsible genetic variation. We also characterized kinetics of the expressed DDC mutant 
enzyme. Systematic polymorphism screening across the 15-Exon DDC locus revealed a single coding 
variant in Exon-14 that was associated with DA excretion and multiple other renal traits indicating 
pleiotropy. When expressed and characterized in eukaryotic cells, the 462Gln variant displayed lower 
Vmax (maximal rate of product formation by an enzyme) (21.3 versus 44.9 nmol/min/mg) and lower 
Km (substrate concentration at which half-maximal product formation is achieved by an enzyme.)
(36.2 versus 46.8 μM) than the wild-type (Arg462) allele. The highly heritable DA excretion trait is 
substantially influenced by a previously uncharacterized common coding variant (Arg462Gln) at the 
DDC gene that affects multiple renal tubular and glomerular traits, and predicts accelerated functional 
decline in chronic kidney disease.
Dopamine (DA) in the central and peripheral neural systems has an established role in motor and behavior con-
trol. The kidney also possesses a dopaminergic system that seems to be independent from neural DA systems. 
In fact intra-renal production of DA is not regulated by renal sympathetic nerve activity as evidenced by renal 
denervation1. Instead, DA is formed locally in proximal tubule epithelial cells2 from its circulatory precursor 
levodopa (L-DOPA) after filtration at the glomerulus. L-DOPA is transported into tubular cells, where it is decar-
boxylated to DA by the enzyme DOPA Decarboxylase (DDC), which is regulated by dietary sodium (Na+)3,4. 
DA then exits these cells across apical and basolateral surfaces to exert paracrine actions via G-protein coupled 
DA receptors, predominantly dopamine receptor1(DRD1) across the nephron, signaling largely through Gs to 
adenylyl cyclase5. The renal dopaminergic system is thus a physiological regulator of Na+ excretion through 
inhibition of tubular Na+ reabsorption.
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Dopaminergic actions in the kidney are not limited to maintaining Na+ homeostasis. DA may increase glo-
merular filtration rate (GFR) by post-glomerular (efferent) arteriolar constriction6 and modulates renin expres-
sion7 as well as angiotensin II, also controlling Na+ excretion and blood pressure (BP)8,9.
Not surprisingly, defects in renal DA production or receptor signaling are linked to development of hyperten-
sion10–12 In animal models intra-renal DA production is linked to development of hypertension and decreased 
longevity13, as well as angiotensin II-mediated renal injury14 and progression of nephropathy15.
We used a classical twin design approach to ask whether renal DA synthesis and excretion are heritable, and 
we performed a genetic association analysis to determine specific effects of the DDC locus on the urinary DA 
trait. Finally, we have performed a functional analysis of 462Gln DDC variant.
Methods
All protocols were approved by the appropriate committees of the University of California – San Diego, Human 
Research Protection Program (HRPP), and each subject gave written informed consent prior to participation.
Subjects and clinical characterization. Twin and sibling subjects. The University of California, San 
Diego (UCSD) twin/sibling study has previously been described16. Twin and sibling participants were recruited 
from southern California by access to a population birth record-based twin registry17, as well as by newspaper 
advertisement as described previously18. Subjects included both dizygotic (DZ) and monozygotic (MZ) twin 
pairs. Zygosity of twins was confirmed genetically by microsatellite and SNP markers18. Clinical characterization 
was conducted as previously described18. BP status (high vs. normal) was defined by history (medical record or 
self-report), presence of antihypertensive medications, and measurement of seated BP by arm cuff [hypertension: 
either/or ≥140/≥90 mmHg systolic BP (SBP)/diastolic BP (DBP), or both]. None of the subjects had a history of 
cardiovascular disease or renal failure, and plasma creatinine concentrations were ≤1.5 mg/dL. Estimated glo-
merular filtration rate (eGFR) was estimated by the MDRD (Modification of Diet in Renal Disease) algorithm.
Twin/sibling physiological phenotyping. Brachial cuff BPs with SBP/DBP measured as K1/K4, as well as heart 
rate, were obtained non-invasively in seated subjects in triplicate using an oscillometric device (DynaPulse; 
PulseMetric Inc., Vista, CA) as described16. Triplicate values (within ±10% of the mean) were averaged. We and 
others previously validated DynaPulse measurements against more invasive devices16,19.
Twin/sibling biochemical phenotyping. Subjects were instructed to fast during the 6 h preceding the evaluation. 
Fasting blood and freshly voided urine samples were collected from each subject. Plasma and urine samples 
were quickly frozen to −70 °C, in preparation for later catecholamine assay at the same time. A sensitive radio-
enzymatic assay was used to measure plasma and urine catecholamines [dopamine (DA), norepinephrine (NE), 
and epinephrine (EPI)] through the catechol-O-methylation process20. The radioenzymatic assay for catecho-
lamines involved transfer of a 3H label to catecholamines from S-adenosylmethionine during O-methylation, 
mediated by the enzyme catechol-O-methyltransferase (COMT). Prior to O-methylation, plasma catecholamines 
were extracted into dilute acetic acid to remove COMT inhibitors in plasma. Assay sensitivities (lower limits of 
detection) were ~10 pg for DA and NE, and ~6 pg for EPI. Inter-assay coefficients of variation were ~10% for 
urine DA, ~20% for plasma DA, ~10% for NE and ~13% for EPI. Plasma and urine creatinine were measured by 
autoanalyzer (Beckman-Coulter; Brea, CA), and urine catecholamine results were normalized to creatinine in 
the same sample.
Genotyping of the DDC locus. We obtained the exon/intron structure for human DDC, as well as puta-
tive sequence, at http://genome.ucsc.edu, focusing on the longer kidney/liver (~107 kbp) isoform (RefSeq 
NM_001082971.1).
Genomic deoxyribonucleic acid (DNA) from twin and sibling pairs was isolated from blood leukocytes with 
Qiagen columns, after proteinase K digestion, as previously described18. SNP genotyping across the DDC locus 
was accomplished using the Illumina 610-Quad genotyping array www.Illumina.com. DDC LD blocks are dis-
played in Supplementary Information Fig. 1.
Systematic polymorphism characterization across the DDC locus. After initial positive DDC-on-DA excretion 
association we searched for functional variants across the DDC locus by re-sequencing exons, untranslated 
regions (UTRs), and promoter, in 12 subjects who carried the trait-associated (minor) allele in intron-8 tagging 
SNP rs11575358 (G > A), versus 11 subjects who did not carry this allele. A public draft of the human21 genome 
sequence was obtained from the UCSC Genome Bioinformatics website http://genome.ucsc.edu and used as 
a scaffold for primer design and sequence alignment. Positions were numbered with respect to the messenger 
ribonucleic acid (mRNA) cap (transcriptional initiation) site in national Center for Biotechnology Reference 
Sequences (NCBI RefSeq) source clone NM_001082971.1 (kidney and liver splicing isoform), using polymerase 
chain reaction (PCR) primers designed by Primer322 to span each of the 15 exons, and 50–100 bp of flanking 
intronic sequences, as well as 965 bp of the proximal promoter (upstream of the cap site). Primers are shown in 
Supplementary Table 1. PCR, amplicon purification and analysis of target sequences were performed according 
to the protocol described previously23. Sequence was determined on an ABI-3730XL dideoxy capillary sequencer. 
Polymorphism and heterozygosity were visualized from the ABI tracings using Codon Code Aligner http://www.
codoncode.com/aligner.
Genotyping of coding variant Arg462Gln (rs11575542, G/A) in DDC exon-14. An amplified fragment length 
polymorphism (AFLP) analysis was also used to genotype the Arg462Gln at the DDC locus, with forward primer 
5′-ggcttcttcctgatgtacgg-3′, and reverse primer 5′-aataaggaagagaaggccgg-3′. Following PCR (30 plus cycles) and 
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digestion with restriction enzyme StuI (1 unit, 2 hours), 2% agarose gel electrophoresis separated restriction frag-
ments. Genotyping yielded a single 482-bp fragment for G/G (Arg/Arg, major allele) homozygotes; two shorter 
fragments (257 and 225 bp) for A/A homozygotes (Gln/Gln); while G/A heterozygotes (Arg/Gln) displayed 3 
fragments (482, 257, and 225 bp) (Supplemental Fig. 2).
Replication of marker (DDC)-on-trait (DA) association. MariMRSnes. US Marines (all young 
healthy men) from the Marine Resiliency Study (MRS) http://marineresilience.org/24 were evaluated. Of 2600 
Marines assessed at pre-deployment for MRS on bases in Southern California, 361 were included in this anal-
ysis. Participants were healthy males of self-identified European (white, non-Hispanic) ancestry, ranging in age 
from 18–37 years (mean 21.7 ± 2.5 years). Biological samples including freshly voided urine, nucleated cells from 
whole blood (for genomic DNA) and EDTA plasma by venipuncture were collected for further analysis.
Caregivers. The study population included caregivers from The Alzheimer Caregiver Coping Study25, conducted 
at UCSD. To be eligible for the study, participants were required to be at least 55 years of age, married, and pro-
viding in-home care for their spouses. Participants were excluded if they were diagnosed with a serious medi-
cal condition, had hypertension greater than 200/120 mmHg, or if they were taking anti-coagulant medication 
(exclusion criteria due to other data collected for this prospective study).
Statistical analyses. Heritability (h2) and genetic covariance. Heritability (h2) estimates of physiologi-
cal and biochemical traits were obtained through twin pair (MZ or DZ) variance components in Sequential 
Oligogenic Linkage Analysis Routines (SOLAR)26 available at http://solar.txbiomedgenetics.org. Heritability is 
estimated by the equation: h2 = VG/VP, where VG is additive genetic variance and VP is total phenotypic variance. 
Here a normal distribution in twin pairs is assumed in order to maximize the likelihood with a mean dependent 
on traits of interest. Genetic covariance of DA excretion with other correlated heritable traits was estimated as ρG 
in SOLAR, while environmental covariance was estimated as parameter ρE.
SNP-on-phenotype effects across the DDC locus were initially tested in MERLIN v1.1.2 http://www.sph.
umich.edu/csg/abecasis/merlin/ with an additive model, to explicitly account for family structure. Descriptive 
(mean ± SEM) and inferential statistics were computed by generalized estimating equations (GEEs) to account 
for correlated observations within families, using SPSS (IBM Corporation; Armonk, NY) predictive analytics 
software. GEE also tested for allele and diploid genotype effects on specified traits. The SNP was defined as a 
3-level variable representing the three possible genotypes (homozygous variant, heterozygous, and homozygous 
wild-type), initially testing an additive effect in the model. Analyses were adjusted for age and sex. In addition to 
additive models, after inspection of distribution of the observations, heterozygotes and minor (or major) allele 
homozygotes were grouped together, as needed to test dominant/recessive models.
Marker-on-trait association display. Results across the DDC locus, centered on intronic tagging-SNP peak asso-
ciations (e.g., rs11575340) as well as results centering on functional variant Arg462Gln (rs11575542) were dis-
played by local SNAP (SNP Annotation and Proxy Search) plot as described at http://www.broadinstitute.org/
mpg/snap/ldplot.php.
Grouped analysis were carried out testing fixed-effect (i.e., diploid genotype) models in STATA (v12, Stata 
Corp, College Station, TX), after individual study regression analyses in SPSS (v17), incorporating individual 
data to derive significance as well as pooled genotype effect size (beta, or slope/allele) and its SE (standard error).
Bioinformatics. To determine conservation of sequence at the functional coding genetic variant (Arg462Gln) 
and local homology, we performed sequence searches using BLASTP http://blast.ncbi.nlm.nih.gov, followed by 
multiple sequence alignments with CLUSTAL Omega (1.1.0) http://www.ebi.ac.uk/Tools/msa/clustalo/.
Human DDC enzyme (EC 4.1.1.28) coding genetic variant Arg462Gln (rs11575542): 
Mutagenesis, eukaryotic expression, and characterization of enzymatic kinetics. Site-directed 
mutagenesis. The full-length human DDC cDNA DNA clone, was obtained from a human pheochromocy-
toma cDNA library, and code for a 480 amino acid protein with a predicted molecular mass of ~53.9 kDa. The 
cDNA was inserted (in the correct 5′ → 3′ orientation) into a eukaryotic (pSV40 promoter) expression plasmid, 
as previously described13. The wild-type (Arg462) version was used as a template for site-directed mutagenesis 
(QuikChange, Agilent) to create the 462Gln variant, which was verified by dideoxy-sequencing.
COS cell transfection and electrophoresis. COS cells were transfected with the pSV40 DDC expression plasmids 
with a modified calcium-phosphate procedure as described13, followed by cell lysis, SDS-PAGE electrophoresis, 
protein transfer to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA), and either protein staining 
(coomassie blue) or detection by immunoblotting with a rabbit anti-human DDC polyclonal antibody, to visualize 
the previously described Mr ~ 50 kDa immunoreactive band. We also detected beta-actin with an anti-beta-actin 
monoclonal antibody (Sigma A5441, St. Louis, MO) to normalize the expression level of DDC protein in COS 
cells, with protein loads of 25, 50, and 100 µg protein/lane (in triplicate).
Expressed human DDC enzyme (EC 4.1.1.28) kinetics: Vmax and Km. COS-cell-expressed DDC (Arg462 ver-
sus Gln462) gave rise to enzymatic activity that catalyzed the decarboxylation of L-3,4-dihydroxyphenylalanine 
(L-DOPA) to DA, at pH 6.5 in the presence of cofactor pyridoxal phosphate (10 µM). Cell lysates were prepared 
and enzymatic activity (including Km (substrate concentration at which half-maximal product formation is 
achieved by an enzyme) as a function of substrate concentration, and Vmax (maximal rate of product formation 
by an enzyme) at saturating substrate concentration). Km and Vmax values were calculated using a Hanes-Woolf 
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plot. Vmax results were normalized to DDC protein expression, determined by immunoblot DDC/beta-actin 
ratio (in triplicate).
After transfection of COS cells with DDC-expression plasmid, we performed a Western blotting to estimate 
the expression levels of wild type (WT) or variant DDC protein. The expression level of variant DDC was 83% less 
than that of WT DDC (as shows in the results), probably caused by the differences in transfection efficiency and 
the copy number of expression plasmids in the cells. We assayed the DDC activity in the same lysates of trans-
fected COS cells, and determined Km and Vmax values of each lysate. Then, the Vmax value of variant DDC was 
divided by 0.83 to normalize with the expression level of WT DDC.
Results
Renal DA excretion: Heritability (h2) and genetic covariance. Twin pairs variance component anal-
yses indicated that catecholamine secretion and renal excretion traits were all substantially heritable (Table 1, 
Fig. 1A), with DA excretion heritability (h2 = VG/VP) = 62.7 ± 5.2% of trait variance (p = 5.96E-16). Notably, the 
renal and plasma DA traits did not significantly correlate, nor did they display shared heritability (genetic covar-
iance), reinforcing the separate control of the two systems.
Renal DA excretion: Cis-QtL at the DDC locus. During dense SNP genotyping across the DDC locus 
(Fig. 1B), we observed a broad DDC marker-on-DA trait association peak in twin/sibling pairs (Fig. 1C) spanning 
the ~107 kbp DDC locus, but confined to a ~275 kbp linkage disequilibrium (LD) block at the locus, as defined by 
the local recombination pattern (cM/Mb tracing). A peak tagging SNP (rs11575340, within intron-5) was highly 
associated with urine DA excretion levels (p = 1.135E-06). By contrast, the plasma DA trait did not display asso-
ciation with the DDC locus (all p > 0.05). Other DDC SNPs “tagging” the urinary DA trait at high significance 
(p < 1.0E-05) were rs11575358 (intron-8), rs11575522 (intron-12), and exonic SNP Arg462Gln (rs11575542, 
exon-14). The association of DDC with DA excretion was confirmed with additional independent groups (Twins/
siblings, Marines, and caregivers) using tagging SNPs rs11575358 and rs11575522. Grouped analyses indicate 
significant associations for each marker SNP rs11575358 (p = 1.0E-04 OR: 0,879), and rs11575522 (p = 1.0E-04 
OR: 0,890) (Table 2).
The trait-associated DDC region on chromosome 7p12, was also plotted in CEU subjects at www.HapMap.org 
as pair-wise LD parameter R2 across the ∼107 kbp locus (Supplemental Fig. 1), indicating a substantial LD block 
spanning the locus.
Trait aggregation with DA excretion: Stratification by urine DA quantiles. We next asked whether 
other traits were associated with DA excretion. Table 3 provides a description of the twin/sibling cohort, divided 
into two groups (quantiles, upper and lower) stratified around the DA excretion median value. Elevated urine 
DA was substantially more common in women than men (p = 1.5E-07), a trend borne out by direct comparison 
of excretion in women versus men (173.1 ± 3.68 versus 134.6 ± 5.49 ng/gm, p = 1.0E-5). Participants with higher 
DA excretion showed significant (p < 0.05) elevations in several other traits, including urine catecholamines (NE 
and EPI), excretion of K+, Na+, and Cl−, as well as the fractional excretion of Na+ (FENa+) (though not frac-
tional excretion of Li+. (FELi+)), and eGFR.
Trait
Correlation with 
uDopamine/creat Trait heritability (h2)
Rho_E (environmental 
covariance) Rho_G (genetic covariance)
n (individuals)
Spearman 
Rho P-value Estimate SEM P-value Estimate SEM P-value Estimate SEM p
Urine catecholamine
uDA/creat — — 0.627 0.052 5.96E-16 — — — — — — —
uNE/creat 0.381 1.74E-12 0.490 0.074 1.00E-07 0.264 0.089 4.70E-03 0.612 0.089 6.33E-08 325
uEpi/creat 0.530 2.44E-24 0.781 0.035 2.16E-24 0.548 0.068 1.07E-09 0.541 0.068 1.71E-09 325
Plasma catecholamine
pDA 0.104 6.83E-02 0.565 0.056 1.82E-13 0.294 0.086 1.48E-03 −0.020 0.108 8.52E-01 346
pNE −0.017 7.62E-01 0.652 0.050 3.19E-16 −0.061 0.092 5.09E-01 0.043 0.105 6.78E-01 355
pEPI −0.120 3.33E-02 0.665 0.051 5.09E-16 0.068 0.092 4.57E-01 −0.066 0.107 5.40E-01 353
Renal
eGFR (MDRD) 0.166 2.94E-03 0.662 0.049 3.59E-17 0.193 0.088 3.34E-02 0.266 0.098 1.01E-02 347
uAlbumin/creat 0.234 2.35E-05 0.357 0.085 7.56E-05 0.175 0.091 5.93E-02 0.200 0.136 1.54E-01 369
FELi+ 0.269 2.02E-05 0.390 0.083 3.06E-05 0.237 0.096 1.88E-02 0.296 0.109 1.12E-02 341
FENa+ 0.216 2.08E-04 0.321 0.083 2.29E-04 0.269 0.091 5.32E-03 0.210 0.134 1.38E-01 347
Table 1. Heritability h2 and genetic covariance: Shared genetic and environmental co-determination for traits 
correlated with urinary dopamine excretion. Covariance estimates (±SEM) are from analyses in SOLAR. 
Heritability, shared genetic determination (genetic covariance, ρG also known as pleiotropy) and environmental 
determination (environmental covariance, ρE) for traits correlated with urine DA excretion are indicated. ρG and 
ρE are fractions, scaled from −1 to 0, and 0 to +1, as determined in SOLAR. Spearman non-parametric trait-
on-trait correlations (Rho) are also reported. MDRD, algorithm for eGFR. Significant differences (p < 0.05) are 
bold. Analyses were undertaken in MZ and DZ twin pairs of European ancestry.
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However, subjects with increased DA excretion did not display changes in circulating catecholamines (includ-
ing plasma DA) or components of the renin-angiotensin-aldosterone system), BP or heart rate (HR).
Visual display of trait aggregation for excreted DA (p = 1.0E-06) with NE (p = 1.0E-06) and EPI, (p = 1.0E-06), 
is given in Supplemental Fig. 3a. Supplemental Figure 3b displays the significant correspondence of urine DA with 
urine Na+ excretion (p = 1.0E-06) and FENa+: increasing levels of excreted Na+ led to higher FENa+ (p = 0.019). 
Supplemental Figure 3c displays urine DA and eGFR coordinately increasing (p = 9.0E-03). The effect on glomerular 
function is reflected in the excretion of other electrolytes: K+ (p = 0.019) and Cl− (p = 1.0E-06) (Table 3).
systematic polymorphism discovery across the DDC locus. In 23 unrelated individuals (n = 46 chro-
mosomes) stratified by presence/absence of DDC rs11575358 trait-associated (“risk”, A, minor) allele (11 with, 
12 without), the promoter and all 15 exons and adjacent intronic regions were re-sequenced. The 17 amplicons 
and their sequencing directions are represented in Fig. 1B. As shown in Table 4 a total of 17 polymorphisms were 
detected. Of these, two common variants were discovered in the promoter: a common SNP (rs56233242, G-899T) 
and an Insertion/Deletion (Ins/Del) variant (rs76759613, G-554/−). We identified 2 non-synonymous (amino 
acid replacement) SNPs, one previously known and located in exon-2 (E2-206; G/A, Val60Met) and a previously 
uncharacterized SNP located in exon-14 (rs11575542, E14-143; G/A, Arg462Gln). We also found a second novel 
SNP in intron-3 (I3-21; C/T) and a common five-base Ins/Del in intron-9 (rs59827423, I9-107; CAGGG/−). The 
other 10 SNPs detected were common and intronic.
Figure 1. Renal DA excretion: Effects of heredity and the DDC gene. (A) Heritability (h2) of catecholamine 
secretion and urinary excretion. Results for plasma catecholamine concentrations (pg/ml) and urine 
catecholamine excretion (ng/gm creatinine) emerge from variance components analyses by SOLAR in MZ 
versus DZ twin pairs. h2 is expressed as % of trait variance attributable to gene action, ±SEM. VG: genetic 
variance; VP: total phenotypic variance. (B) Human DOPA decarboxylase (DDC): Exon/intron and inter-
species sequence conservation. Polymorphism discovery across the human DDC locus: re-sequencing strategy. 
There are 15 exons at human DDC. Eighteen polymerase chain reaction amplicons spanned the promoter and 
coding regions. Amplicons with double arrows were read in both directions. The SNP Arg462Gln (rs11575542) 
characterized in this paper is located in exon-14. (C) Natural genetic variation at DOPA decarboxylase (DDC, 
AADC) on chromosome 7p12: Prediction of renal DA production in twin pairs. Local region of the Manhattan 
plot displayed by SNAP (SNP Annotation and Proxy Search) plot http://www.broadinstitute.org/mpg/snap/
ldplot.php. The peak association (p = 1.35E-06; see diamond) was at DDC intron-5 tagging SNP rs11575340. 
The DA secretion trait-associated coding variant (characterized in this paper) is at DDC Arg462Gln (exon-14, 
rs11575542). Marker-on-marker LD is shown as R2 (with respect to rs11575340), on a red color scale.
Group
DDC 
variant
Alleles, Minor/
Major
Minor allele 
frequency N Trait
Beta  
(slope per allele)
SE  
(of beta) P-value OR 95% CI
Twins/siblings rs11575385 T/C 3.48% 453 Urine DA/creat −0.173 0.030
Marines/MRS rs11575385 A/G 1.72% 228 Urine DA/creat 0.080 0.064
Caregivers rs11575385 A/G 0.68% 132 Urine DA/creat −0.234 0.317
Result rs11575385 — — 813 Urine DA/creat −0.129 0.027 <0.0001 0,879 (0,834;0,927)
Twins/siblings rs11575522 T/C 2.90% 453 Urine DA/creat −0.16 0.031
Marines/MRS rs11575522 A/G 2.16% 229 Urine DA/creat 0.040 0.060
Caregivers rs11575522 A/G 1.37% 132 Urine DA/creat −0.1034 0.226
Result rs11575522 — — 813 Urine DA/creat −0.116 0.028 <0.0001 0,890 (0,843;0,941)
Table 2. Replication of the effects of DOPA decarboxylase (DDC) tagging variants on renal dopamine 
excretion: Grouped analysis of 3 independent population groups. Effects of DDC tagging variants rs115575385 
(28 kb from peak tagging SNP for urine DA excretion, rs11575340) and rs11575522 (61 kb from peak tag SNP 
rs11575340) on urine DA excretion in three independent groups, analyzed with STATA. MRS indicates Marine 
Resiliency Study; DA/creat, DA excretion normalized to creatinine in the same urine sample. Significant 
(p < 0.05) effects are given in bold type. During analyses, tests of potential heterogeneity of samples were 
positive for both rs11575386 (Q statistic = 12.9, df = 2, p = 0.002) and rs11575522 (Q = 8.85, df = 2, p = 0.012).
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We selected 23 subjects based on genotype, according to trait-associated intron-8 tagging SNP rs11575358 
(G > A): 11 cases (carrying the DA-trait-associated A-allele, one A/A homozygote and 10 G/A heterozygotes) and 
12 controls (G/G homozygotes).
Inter-species amino acid sequence alignments and conservation are presented in Supplemental Table 2. 
Results reveal that Arg 462 is completely in old world primates, though not in new world primates (squirrel 
monkey, marmoset). 462Gln is found in several other mammalian and vertebrate species: mole rat, guinea pig, 
and ricefish. The local region around codon 462 is within a carboxy-terminal alpha-helix (helix-12, amino acids 
457–477) on X-ray crystallography of human DDC.
Pleiotropic effects of DDC genetic variant Arg462Gln on multiple human traits. With diploid 
genotypic ratios of Arg/Arg:Arg/Gln:Gln/Gln at 429:23:1, Arg462Gln (rs11575542) was in Hardy Weinberg equi-
librium (HWE) (Chi2 = 1.32, p = 0.25), with a minor allele frequency of ~2.76%. Its effects on physiological and 
biochemical traits were evaluated in twins/siblings (Table 5), revealing pleiotropic effects of Arg462Gln on mul-
tiple traits.
Traits
Urine dopamine quantiles (median)
P-value
Lower: <153.8 µg/g Upper: •153.8 µg/g
n Mean SEM n Mean SEM
Demographic and Physical
Age, years 185 40.3 1.2 188 39.4 1.2
Sex: 1 = M, 2 = F (M/F) 185 66/119 188 19/169 3.00E-05
BP status, NT/HTN (%) 185 171/14 (92%/8%) 188 168/20 (89%/11%) 2.95E-01
BMI, kg/m2 184 24.7 0.31 184 24.8 0.31 7.57E-01
Biochemical
Catecholamines
   Urine dopamine, µg/g 185 121.9 3.35 185 206.1 3.33 <1.0E-06
   Urine norepinephrine, µg/g 185 24.7 0.75 182 31.6 0.76 <1.0E-06
   Urine epinephrine, µg/g 182 10.8 0.42 182 14.8 0.41 <1.0E-06
   Plasma dopamine, pg/ml 173 19.9 2.07 176 21.9 2.05 5.20E-02
   Plasma norepinephrine, pg/ml 175 307.2 11.1 175 332.5 11.1 2.32E-01
   Plasma epinephrine, pg/ml 178 25.2 1.23 176 26.6 1.24 5.60E-01
Renin–angiotensin system
   Plasma renin, pg/ml 176 19.6 1.18 182 19.3 1.16 9.97E-01
   Plasma aldosterone, pg/ml 177 139.2 5.59 178 127.9 5.57 1.94E-01
Inflammation
   C reactive protein, ng/ml 167 1648.6 184.0 178 2117.0 178.0 4.40E-01
Kidney and urine
   Urine albumin excretion, mg/g 181 8.87 1.93 186 10.31 1.91 6.27E-01
   eGFR (MDRD), ml/min 178 87.8 1.61 181 96.2 1.60 9.00E-03
   Urine K+, mEq/g 185 64.3 2.44 186 73.4 2.43 1.90E-02
   Urine Na+, mEq/g 185 115.9 5.12 186 150.9 5.12 <1.0E-06
   Urine Cl−, mEq/g 184 135.2 5.36 183 170.1 5.32 <1.0E-06
   Urine cortisol, μg/g 132 4.34 0.25 145 3.78 0.24 2.75E-01
   Urine nitric oxide, nmol/g 177 1035.7 54.2 181 1213.8 53.6 8.70E-02
   FELi+, % 120 24.8 4.44 140 24.1 4.09 4.47E-01
   FENa+, % 161 1.59 0.19 163 2.23 0.19 1.90E-02
Physiological
Hemodynamics
   Systolic BP, mmHg 170 122.6 0.99 177 123.1 0.86 5.19E-01
   Diastolic BP, mmHg 171 76.3 0.64 178 93.7 0.83 4.55E-01
   Heart rate, beats/min 178 60.1 0.79 182 69.9 0.86 4.55E-01
Table 3. Urine dopamine quantiles: Effects on demographic, biochemical and physiological traits. Results for 
twin/sibling study population, divided about the median value for urine DA excretion. Descriptive (mean ± 
SEM) and inferential statistics (p-values) for twins/siblings were derived from generalized estimating equations 
(GEE) to account for correlations within nuclear families. Numbers (n) describes the number of individuals 
analyzed. BP indicates blood pressure; NT, normotensive; HTN, hypertensive; CRP, C reactive protein; eGFR 
MDRD, estimated GFR; FELi+, fractional excretion of lithium; FENa+, fractional excretion of Na+; NO, nitric 
oxide; DBP, diastolic blood pressure; SBP, systolic blood pressure; HR, heart rate; BMI, body mass index; SV 
resistance, systemic vascular resistance. Significant differences (P <0.05) are in bold type.
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Notable effects were observed in the renal excretion traits. Carriers of the 462Gln (minor) allele (heterozygous 
[n = 23] or homozygous [n = 1]) showed increased DA and EPI excretion. Directionally coordinate effects on 
eGFR and urine DA are depicted in Fig. 2A. Figure 2B displays parallel effects on albumin excretion and FELi+, 
an index of proximal tubular avidity for Na+. Thus 462Gln-augmented renal DA synthesis and excretion may give 
rise to a cascade of events in the kidney: local DA may trigger both natriuresis and afferent arteriolar vasodilation 
(or efferent constriction), and the ensuing glomerular hyperfiltration increases albumin excretion.
Notably, DDC variant Arg462Gln did not affect plasma catecholamine (including plasma DA) concentrations, 
the renin-angiotensin system (plasma renin and plasma aldosterone), c-reactive protein (CRP) levels, or systemic 
hemodynamic traits (BP and HR) (Table 5).
Human DDC variant enzyme kinetics. Expression. Figure 3A shows immunoblot results of human 
DDC protein expression in COS cells: wild-type (Arg462) and variant (Gln462), with beta-actin control normal-
ization. Figure 3B shows the results of the quantifying the expression of DDC in transfected cos cells in controls 
(column 1), wild type (Arg462) and variant (462Gln), with a higher expression in wild type cells.
Kinetics. We analyzed the kinetic parameters comparing wild-type and variant enzymatic action using L-DOPA 
as substrate (Fig. 3C), using a Hanes-Woolf plot. The 462Gln variant displayed a substantially lower Vmax (at 
19.4 ± 0.2 versus wild-type 29.8 ± 0.3 nmol/min/mg protein; 35% reduction at p < 0.0001), though similar Km 
(at 31.0 ± 5.3 versus wild-type 31.6 ± 4.6 μM).
Discussion
The independent renal DA system highly expressed in proximal tubule subserves both tubular and glomerular 
functions. Intra-renal DA also influences the renin-angiotensin system and thereby controls progression of renal 
damage in kidney pathologies14,15.
The role of common genetic variation in control of endogenous dopaminergic activity is previously unex-
plored. In the twin study, we first determined that DA excretion is a highly heritable trait (at 62.7 ± 5.2% of 
trait variance, p = 5.96E-16), although it was genetically uncorrelated with plasma DA. We then characterize 
a functional non-synonymous variant (Arg462Gln) in the DDC coding region that seems to control common 
heritable variation in DA secretion and its downstream renal consequences in an apparently healthy population. 
Replication was performed with a grouped analysis of three independent cohorts that validated the findings 
(Table 2).
Genetic variant Allele Codon Diploid genotypes Statistics
SNP#
Position −/+ 
cap site RefSNP_# Major Minor
SNP 
location Codon-1 Codon-2 Codon #
Amino 
acid_1
Amino 
acid_2
“Controls” (G_allele 
at tagging rs11575385; 
N = 12)
“Cases” (A_allele at 
tagging rs11575385; 
N = 11)
Fisher Exact Test 
P-value (case 
versus control)
1 −899 rs56233242 G T Promoter 6_G/G, 4_T/G, 2_T/T 2_G/G, 3_T/G, 6_T/T 0.26635
2 −554 rs76759613 G — Promoter 3_G/G, 7_G/−, 2_−/− 7_G/G, 4_G/− 0.13980
3 E2-206 New G A Exon_2 GTT ATT 60 Val Ile 11_G/G, 1_G/A 11_G/G 1.00000
4 I2-37 rs11575293 A G Intron_2 12_A/A 2_A/A, 8_G/A, 1_G/G 0.00007
5 E3-33 rs11575302 C T Exon_3 GCC GCT 78 Ala Ala 12_C/C 1_CC, 9_C/T, 1_T/T 0.00003
6 I3-21 New C T Intron_3 12_C/C 10_CC, 1_T/C 0.47826
7 I4-16 rs11575334 T C Intron_5 2_T/T, 6_T/C, 4_C/C 4_T/T, 6_T/C, 1_C/C 0.35444
8 I5-42 rs3735273 A G Intron_5 5_G/G, 6_A/G, 1_A/A 2_G/G, 5_AG, 4_A/A 0.23631
9 I6-22 rs11575375 T C Intron_7 6_C/C, 4_T/C, 2_T/T, 6_T/C, 5_T/T 0.14045
10 I8-84 rs11575392 A G Intron_8 6_A/A, 5_A/G, 1_G/G 8_A/A, 2_A/G, 1_G/G 0.40032
11 I9-63 rs4947580 G A Intron_9 12_G/G 10_G/G, 1_G/A 0.23913
12 I9-107 rs59827423 CAGG — Intron_10
3_CAGGG/CAGGG, 
5_CAGGG/−, 2_−/− 
(two missing)
6_CAGGG/−, 5_−/− 0.38128
13 I9-23 rs11575457 T G Intron_10 4_T/T, 6_T/G, 2_G/G 4_T/G, 7_G/G 0.01100
14 I11-9 rs11575482 G A Intron_11 6_G/G, 1_A/A, 5_A/G, 7_G/G, 4_A/G, 1.00000
15 E14-143 rs11575542 G A Exon_14 CGG CAG 462 Arg Gln 12_G/G 1_GG, 9_G/A, 1_A/A 0.00001
16 I14-42 rs11575543 C T Intron_14 12 _C/C 8_C/C, 2_C/T, 1 T/T 0.09317
17 E15-323 rs11575551 C T Intron_15 9_C/C, 3_C/T 7_C/C, 4_C/T 0.66685
Table 4. Summary of systematic DOPA decarboxylase (DDC) polymorphism determination by re-sequencing 
across the locus: Discovery of trait-associated coding variant Arg462Gln. The location for each polymorphism 
is given, and their positions are numbered upstream (−) or downstream (+) of the cap (transcription initiation) 
site. For each SNP, the reference number (RefSNP) is given where available in the public database, and novel 
polymorphisms are indicate as “New”. Nucleotide deletion is indicated by “−”. The Fisher Exact Test P values 
compare individuals carrying/not carrying the risk (A, minor) allele at tagging intronic polymorphism 
rs11575385 (G > A).
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The paradox of elevated DA excretion in DDC deficiency. We observed a DDC genetic variant 
(Arg462Gln) wherein the minor allele (462Gln) seemed to increase renal DA production but reduce enzymatic 
DDC activity. Mendelian human autosomal recessive DDC deficiency is characterized by predominantly neuro-
logical manifestations such as developmental delay, prominent motor abnormalities, oculogyric crises and auto-
nomic features27,28. Available treatment options (DA agonists, vitamin B6 and monoamine oxidase inhibitors) 
are only variably effective29. However, many such DDC-deficient patients exhibit normal or even elevated levels 
of urinary DA excretion in the presence of a less active DDC with normal levels of plasma DA30. Such findings 
have been referred to the “paradox of hyperdopaminuria in DDC deficiency”. Clues to the origin of this paradox 
involve the presence of a separate/local renal DA system synthesizing the transmitter in proximal tubular epithe-
lial cells of the kidney cortex31. This local kidney system displays high efficiency in transforming blood-derived 
L-DOPA to renal DA. As a consequence of systemic DDC deficiency in the brain and elsewhere, more substrate 
(L-DOPA) and cofactors may be delivered to DDC in the kidney cortex32. Other theories propose alternative 
substrates for renal DA formation such as 3-methoxy-tyrosine33, other metabolic pathways such as tyramine 
hydroxylation by renal CYP2D6 to form DA34 or even tyrosinase as an alternative pathway for DOPA and DA 
synthesis even in the absence of tyrosine hydroxylase35.
Traits
Arg462Gln (G>A) diploid genotype
P-value
Arg/Arg (G/G) Gln/Arg (G/A) or Gln/Gln (A/A)
n Mean SEM n Mean SEM
Demographic and Physical
Age, years 429 40.1 1.41 24 38.1 2.3 3.57E-01
Sex: 1 = M, 2 = F 110/31 — — 18-Jun — — 9.44E-01
BP status, NT/HTN 384/45 — — 23/1 — — 3.18E-01
BMI, kg/m2 423 24.9 0.224 24 26.2 1.1 1.29E-01
Biochemical
Catecholamines
   Urine dopamine, μg/g 429 150.3 2.52 24 208.3 10.3 3.68E-05
   Urine norepinephrine, μg/g 423 28.2 0.576 23 26.5 2.13 4.40E-01
   Urine epinephrine, μg/g 419 10.9 0.237 24 15.7 1.21 1.06E-03
   Plasma dopamine, pg/ml 401 11.4 0.017 22 10.6 0.073 6.67E-01
   Plasma norepinephrine, pg/ml 403 325.5 6.99 23 276.4 29.3 1.44E-01
   Plasma epinephrine, pg/ml 405 21.1 0.663 23 25.9 3.32 4.16E-01
Renin-angiotensin system
   Plasma renin, pg/ml 340 19.6 0.831 18 16.6 3.61 3.62E-01
   Plasma aldosterone, pg/ml 377 134.1 3.7 19 110.5 16.3 3.28E-01
Inflammation
   C reactive protein, ng/ml 389 2.93 0.029 23 3.03 0.121 3.24E-01
Kidney and urine
   Urine albumin excretion, mg/g 439 4.76 0.24 23 6.79 1.55 3.30E-02
   eGFR (MDRD), ml/min 411 94.6 1.22 22 110.5 6.81 3.20E-02
   Urine K+, mEq/g 425 70.3 1.5 23 68.3 6.6 5.01E-01
   Urine Na+, mEq/g 426 129.4 3.34 23 162.9 14.3 1.20E-02
   Urine Cl−, mEq/g 424 149.9 3.5 23 175.1 14.9 5.49E-01
   Urine cortisol, ug/g 265 3.31 0.11 12 2.52 0.23 6.96E-01
   Urine nitric oxide, nmol/g 412 932.8 342 23 1213.5 344.9 1.46E-01
   FELi+, % 248 13.9 0.603 11 23.1 3.2 8.00E-03
   FENa+, % 372 1.79 0.127 18 3.64 0.575 4.70E-02
Physiological
Hemodynamic
   Systolic BP, mmHg 399 123.2 0.63 21 128 2.57 7.33E-01
   Diastolic BP, mmHg 401 75.8 0.46 21 79.1 2.11 7.05E-01
   Heart rate, beats/min 412 69.1 0.51 23 74.5 2.17 4.76E-01
Table 5. Genetic marker-on-trait associations between DDC coding variant Arg462Gln (rs11575542, G > A) 
and phenotypes in twins and siblings. Numbers (n) describe number of individuals analyzed for that genotype 
and trait. BP indicates blood pressure; NT, normotensive; HTN, hypertensive; CRP, C reactive protein; eGFR, 
estimated GFR; FELi+, fractional excretion of Li+; FENa+, fractional excretion of Na+; NO, nitric oxide; DBP, 
diastolic blood pressure; SBP, systolic blood pressure; HR, heart rate; BMI, body mass index. Entries reflect 
mean ± one SEM. Significant (p < 0.05) differences are indicated in bold type. Descriptive statistics emerged 
from GEE. Inferential statistics (p-values) emerged from MERLIN, except for FELi+ and FENa+ (from GEE) 
and urine albumin excretion (by non-parametric Kruskal-Wallis test).
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Selective kidney DDC loss-of-function in experimental animals: Renal functional consequences. 
The DDC 462Gln allele elevate DA eGFR and albumin excretion in healthy individuals (Table 5, Fig. 2B). These 
results suggest that glomerular hyperfiltration may be a risk factor for accelerated renal decline in 462Gln car-
riers36. By contrast, after selective loss of intra-renal DA production by targeted ablation of the DDC gene in 
the proximal tubule, transgenic mice display protection from renal injury induced by angiotensin II14 or during 
diabetic nephropathy15.
Why might humans and mice display such apparent differences in renal effects of intra-renal DA deficiency? 
First of all, in the mouse, DDC ablation could be created precisely in the proximal tubule by targeting the knock-
out to cells expressing the Cre recombinase driven by a proximal tubule-specific (γ-GT) promoter37, while 
Figure 2. Association of DDC genetic variant Arg462Gln (rs11575542) with DA excretion and renal function. 
Results are shown as mean ± SEM in twins/siblings. Numbers are in parentheses (n) indicate the n for the 
observation. Significant differences (p < 0.05) are in bold. (A) Pleiotropic effects on urine DA excretion, 
p = 3.68E-05, and eGFR, p = 0.032. Minor allele homozygotes Gln/Gln (A/A) and heterozygous Arg/Gln (G/A) 
subjects displayed increased eGFR and urine DA excretion compared to homozygous major allele Arg/Arg 
(G/G) subjects. (B) Pleiotropic effects on FELi+ (p = 0.008) and urine albumin excretion (p = 0.033). Minor 
allele homozygotes (Gln/Gln, A/A) and heterozygotes (Arg/Gln, G/A) displayed increased FELi+, as well as 
urine albumin excretion, compared to major allele homozygotes (Arg/Arg, G/G).
Figure 3. Human DDC enzyme genetic variants. (A) Expression of human DDC protein in COS cells: Detection 
by anti-AADC immunoblot, normalized with beta-actin. Protein standard size ladders bracket the experimental 
results. C (control), W (wild-type, Arg462), and V (variant, 462Gln). Blots were initially examined at protein loads 
of 25, 50, and 100 µg protein/lane; here, triplicate determinations for 50 µg protein loads are shown, along with 
size standards. (B) Quantifying expression of DDC expressed in COS cells: Wild-type (Arg462) versus variant 
(462Gln). DDC and beta-actin immunoreactive bands (at 50 µg protein/lane, in triplicate) were scanned for optical 
density, and mean ± one SD values are shown. Expression of 462Gln was ~83% of that for Arg462. (C) Kinetic 
analyses with L-DOPA substrate. Graph shows a Hanes-Woolf plot of [S]/v as a function of [S], where [S] is the 
concentration of substrate [L-DOPA] and v is the reaction velocity (nmol/min/mg) at that [S]. The 462Gln variant 
displays a substantially lower Vmax (at 19.4 ± 0.2 versus wild-type 29.8 ± 0.3 nmol/min/mg protein; 35% reduction 
at p < 0.0001), though similar Km (at 31.0 ± 5.3 vs wild-type 31.6 ± 4.6 μM; p = 0.94). Replicates: at [S] = 0.5, n = 2; 
others, n = 3. Results are shown as mean ± one SD. Since typical L-DOPA substrate concentrations in humans are 
far below the Km value (at L-DOPA of ~1.08 nM [2.13 ng/ml] in plasma and ~100 nM [1.22 µg/hr] in urine, then 
the DDC system is likely to be catalyzing DA synthesis over a relatively linear range in vivo.
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humans express DDC from the same gene in both CNS and kidney. Secondly, our results as well as other human 
studies on the “paradox of hyperdopaminuria in DDC deficiency” indicate that a relatively inactive DDC enzyme 
can actually result in elevated renal DA excretion32 by several proposed mechanisms. Thus, the human and mouse 
results may ultimately be compatible.
Advantages and limitations of this study. Here we were able to mobilize several complementary 
techniques to understand genetic control of renal dopamine excretion: twin pair variance components to esti-
mate heritability, extensive human phenotyping, dense SNP genotyping, validation by grouped analysis of three 
independent groups, systematic polymorphism discovery across the DDC locus, functional testing of a mutant 
enzyme, and extension into a disease population. The non-synonymous amino acid substitution (Arg462Gln) 
occurred in a carboxy-terminal alpha-helix far from the DDC active site38; however, the Arg → Gln substitution 
yields a substantial change in amino acid properties specified by codon 462 (cationic → neutral), and its position 
far from the active site is consistent with the unchanged Km (i.e., no change in substrate affinity) in the face of 
diminished Vmax (i.e., essentially non-competitive or allosteric inhibition).
Nonetheless, questions remain. DDC and DA production are widespread, occurring not just in the kidney, 
but also in liver and in the nervous system. In the intact human organism (as opposed to a more manipulable 
experimental animal) it may be difficult to understand precisely the roles of such different sites of origin of the 
amine. Indeed, there may be other origins of DA, such as tyramine hydroxylation by renal CYP2D634 or even 
tysosinase39. Since there is only a single DDC gene on chromosome 7p12, subserving expression in both brain 
and kidney (albeit with alternative initial exons), and since DDC is in the biosynthetic pathway for serotonin as 
well as dopamine, it is likely that our results also have implications for neuropsychiatric disease; however, in this 
report we confined our investigation to renal traits.
Conclusions and perspectives. We conclude that DDC exon-14 non-synonymous variant Arg462Gln is 
functional and this variant has clinical implications as follows, and it alters enzyme kinetic parameters, Vmax 
Km, resulting in changes in urine DA excretion. The change in DA secretion influences renal function, modifying 
renal tubular avidity for Na+ and Li+, with consequent changes in eGFR and albumin excretion, all this changes 
eventuating in accelerated renal decline in patients with CKD (Fig. 4). These findings augment our understanding 
of the kidney dopaminergic system, and shed new light on the link between DA production and renal dysfunction 
in humans, a topic previously investigated largely in animal models.
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